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Abstract
Background and Aims—Esophageal biopsies in patients with eosinophilic esophagitis (EoE) 
can feel firm, with resistance appreciated when pulling the forceps to obtain the tissue sample. We 
aimed to assess the diagnostic utility of the esophageal biopsy pull sign, and determine its 
histologic associations and response to treatment.
Methods—This was a prospective cohort study of adults undergoing outpatient upper endoscopy. 
Cases of EoE were diagnosed per consensus guidelines and were subsequently treated with either 
topical steroids or dietary elimination. Controls were subjects who did not have EoE. The 
frequency of the esophageal biopsy pull sign was assessed in EoE cases and controls, and 
diagnostic metrics were calculated. The pull sign was also reassessed in cases after therapy.
Results—83 EoE cases and 121 controls were included. 63 EoE cases (76%) were pull sign 
positive compared with just 2 controls (2%; p < 0.001), corresponding to a sensitivity and 
specificity of 76% and 98%, positive and negative predictive values of 97% and 86%, and positive 
and negative likelihood ratios of 45.9 and 0.245. The pull sign was the strongest endoscopic 
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predictor of EoE case status at baseline, and was less frequent after successful treatment (20% vs 
79%; p < 0.001).
Conclusions—The “pull” sign is highly specific for EoE, and is rarely seen in non-EoE 
controls. In patients with EoE who respond to treatment, the pull sign often resolves. The pull sign 
may be a simple and easily obtained measure of esophageal remodeling.
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Eosinophilic esophagitis; biopsy; endoscopy; diagnosis; fibrosis
Introduction
Eosinophilic esophagitis (EoE) is a chronic allergic/immune-mediated condition of the 
esophagus characterized by symptoms of esophageal dysfunction and epithelial infiltration 
of eosinophils in the esophagus.1, 2 The associated endoscopic features of EoE include 
esophageal rings, strictures, diffuse narrowing, linear furrows, white plaques, decreased 
vascularity or edema, and fragile mucosa (“crêpe-paper”).1–3 Although these are 
increasingly recognized signs of EoE, the findings themselves are not specific to the 
condition, differ by age of presentation, and therefore are not currently required for 
diagnosis.4–7
The diverse endoscopic findings of EoE may be related to different aspects of the disease 
pathogenesis. Some can be attributed to its inflammatory component, for example white 
plaques are thought to represent eosinophilic microabscess and eosinophilic exudate.8, 9 
Others can be attributed to fibrosis and esophageal remodeling, such as the rings, strictures, 
and narrowing.6, 10, 11 However, regardless of the endoscopic appearance, the current 
recommendation is that esophageal biopsies are required to demonstrate eosinophilia before 
diagnosing EoE.1, 2 We have recently observed that when obtaining biopsy specimens in 
patients with EoE, the mucosa feels firm, and there can be substantial resistance when 
pulling on the forceps to remove the biopsy sample, particularly when compared with non-
EoE patients. Although this has also been noted in a recent series of EoE patients,12 it is 
unknown whether this finding, termed the esophageal biopsy “pull” sign, has diagnostic 
utility for EoE, whether it represents underlying epithelial fibrosis, or whether it improves 
after treatment.
The aims of this study were to describe the esophageal biopsy pull sign, assess the 
diagnostic utility of this finding, and determine histologic associations and response to 
treatment. We hypothesized that the finding was specific for EoE, that there would be an 
association with lamina propria fibrosis, and that the sign would resolve with successful 
treatment.
Methods
Study design and case definitions
We conducted a sub-analysis of a prospective cohort study conducted at University of North 
Carolina, focusing on patients enrolled from March, 2011, through December, 2013. For the 
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present study, the pull sign was a pre-specified secondary outcome of interest. For the parent 
study, consecutive adults (age ≥18 years) referred for outpatient upper endoscopy were 
recruited if they had symptoms of esophageal dysfunction (ie dysphagia, food impaction, 
heartburn, reflux, or chest pain). Exclusion criteria were: known diagnosis of EoE; known 
diagnosis of a non-EoE eosinophilic gastrointestinal disorder (EGID); known esophageal 
cancer; prior esophageal surgery; GI bleeding; anticoagulation; known esophageal varices; 
medical instability or multiple comorbidities precluding enrollment in the clinical opinion of 
the endoscopist; and inability to read or understand the consent form. This study was 
approved by the UNC Institutional Review Board. Subjects provided informed consent and 
were enrolled before the endoscopy.
Consensus diagnosis guidelines were used to identify cases of EoE.1, 2, 13 EoE cases had to 
have a typical symptom of esophageal dysfunction, an esophageal biopsy with at least 15 
eosinophils per high-power field (eos/hpf) after an 8 week trial of a proton-pump inhibitor 
(PPI; 20–40 mg twice daily of any of the available agents, prescribed at the discretion of the 
clinician), and other causes of esophageal eosinophilia excluded. Therefore, baseline data 
were obtained for cases after the PPI trial, but before knowledge of the biopsy results or 
prescription of EoE-specific treatment. Non-EoE controls were subjects who, after 
endoscopy and biopsy, did not meet clinical and histologic criteria for EoE. Patients with 
PPI-responsive esophageal eosinophilia (PPI-REE) were not included in this analysis.
Clinical, endoscopic, and histologic data
We recorded all data, including demographics, symptoms, atopic conditions, and endoscopic 
findings, using standardized case report forms and a prospectively administered patient 
questionnaire. During endoscopy, esophageal biopsies for research use were obtained (2 
from the proximal, one from the mid, and 2 from the distal esophagus) to maximize EoE 
diagnostic sensitivity.14, 15 Gastric and duodenal biopsy specimens were also collected for 
research purposes to exclude concomitant eosinophilic gastroenteritis. Additional clinical 
biopsy specimens were taken as indicated at the discretion of the endoscopist. All specimens 
were obtained with standard large capacity forceps (RJ4; Boston Scientific; Marlborough, 
Mass).
At the time that biopsy specimens were obtained, the endoscopist (ESD) reported on 
whether the pull sign was positive or negative. Pull-sign data were collected prospectively as 
a pre-specified secondary outcome within the framework of the overall study. A positive 
pull sign was defined by resistance appreciated when obtaining the biopsy specimen. In 
particular, increased force had to be applied by pulling on the forceps to remove the sample 
from the esophageal wall. This was typically associated with the mucosa feeling firm, 
mucosal tenting when the forceps were pulled, and the biopsy forceps being unable to fully 
close (Figures 1A–C; Video). A negative pull sign was recorded when these features were 
not present and there was no resistance when removing the tissue. These definitions are 
consistent with those used in a prior report.12 All patients in this study were assessed for 
their baseline examination before the diagnosis of EoE being known. Therefore, although 
the endoscopist was not formally blinded as to clinical features, case versus control status 
was not known at the time that the pull sign was determined.
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After biopsy specimens were collected, we applied our previously validated methodology to 
quantify the esophageal eosinophil count.16 In brief, slides were masked to case/control 
status, digitized, and reviewed with Aperio ImageScope (Aperio Technologies, Vista, Calif). 
Pathologists also did not have access to clinical findings or endoscopy reports. Five 
microscopy fields from each of the 5 biopsies were examined to determine the maximum 
eosinophil density (eosinophils/mm2). Eosinophil density was then converted to an 
eosinophil count (eos/hpf) using a hpf size of 0.24 mm2, the most commonly reported field 
size in the literature,17 in order to compare results with prior studies. We also recorded other 
histologic findings associated with EoE, including: eosinophilic microabscesses (clusters of 
≥ 4 eosinophils); eosinophil degranulation; basal layer hyperplasia; spongiosis; and lamina 
propria fibrosis (assessed when adequate subepithelial stroma was present).15, 18
Treatment and follow-up
EoE cases who were identified in this study were treated at the discretion of their 
gastroenterologist as clinically indicated. Patients could either receive topical corticosteroids 
(either oral viscous budesonide 1 mg twice daily or fluticasone from a multi-dose inhaler, 
880 mcg twice daily for eight weeks),19–21 or dietary therapy with the six-food elimination 
diet (avoidance of dairy, wheat, egg, soy, nuts, and seafood) for 6 weeks.22, 23 At the end of 
either treatment period, repeat upper endoscopy was performed. During this follow-up 
examination, endoscopic findings and the pull sign were recorded, and esophageal biopsy 
specimens were obtained with a protocol identical to that outlined above. Response to 
treatment was defined histologically as <15 eos/hpf.24
Statistical analysis
Descriptive statistics were used to summarize the clinical, endoscopic, and histologic 
features of the EoE cases and non-EoE controls, as well as to characterize the EoE cases 
who were pull sign positive versus those who were pull sign negative. Means were 
compared with a 2-sample t-test, and proportions were compared with chi-square. To 
compare baseline and follow-up characteristics of the EoE cases, paired t-tests were used for 
continuous variables and chi-square was used for categorical variables.
The frequency of the esophageal pull sign was determined in the EoE cases and non-EoE 
controls. The frequency was also determined in the EoE treatment responders (<15 eos/hpf) 
and non-responders. To assess the diagnostic utility of this sign to predict EoE case status 
(using the consensus diagnostic guidelines as the criterion standard), we calculated the area 
under the receiver operator characteristic curve (AUC) for a positive pull sign. To further 
contextualize this result, we calculated the sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), and the positive and negative likelihood ratios (LR
+; LR−). We also applied the LRs using Bayes Theorem to calculate a range of post-test 
probabilities corresponding to various pre-test probabilities for EoE. Multivariate logistic 
regression was used to determine whether a positive pull sign was an independent 
endoscopic predictor of EoE case status. For this model, all endoscopic findings that 
distinguished cases vs controls at the p<0.05 level were included. Given the subjective 
nature of the pull sign, we collected pilot data to assess interobserver agreement data 
between the corresponding author and 2 additional endoscopists for a subset of patients. 
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Agreement was calculated with the kappa statistic. All analyses were performed with Stata 
(version 9.2; StataCorp; College Station, Tex).
Results
Characteristics of the cases and controls
A total of 204 subjects, 83 EoE cases and 121 controls, had esophageal biopsy pull sign data 
available and were analyzed in this study. Compared with controls, EoE cases were younger 
(38 vs 51 years; p < 0.001), more likely to be male (65% vs 36%; p < 0.001), white (93% vs 
81%; p = 0.02), have dysphagia (96% vs 73%; p < 0.001), and have food allergies (41% vs 
15%; p < 0.001) (Table 1). Only 3 EoE cases (4%) had a normal upper endoscopy, and the 
typical endoscopic findings of EoE were more common in the case group (Table 1). The 
mean of the maximum eosinophilic counts was 144 eos/hpf in the cases and 2 in the controls 
(p < 0.001). In the 46 (58%) EoE cases where sub-epithelial stromal tissue was obtained, 18 
(39%) had lamina propria fibrosis, a finding seen in only 3 (10%) of the controls (p = 
0.004).
Diagnostic utility of the pull sign
There were 63 EoE cases that were pull sign positive (76%) compared with just 2 controls 
(2%; p < 0.001) (Table 2). The AUC for this finding was 0.871, corresponding to a 
sensitivity of 76%, specificity of 98%, PPV of 97%, NPV of 86%, LR+ of 45.9, and LR− of 
0.245. Figure 2 demonstrates how these LRs impact post-test probability for EoE. For a pre-
test probability of 6%, 15%, or 23% (the expected prevalence of EoE in all patients 
undergoing endoscopy,25 and lower and upper bounds of EoE prevalence in patients 
undergoing endoscopy for an indication of dysphagia26–28), the post-test probabilities are 
75%, 89%, and 93%, respectively, with a positive pull sign, and 2%, 4%, and 7% with a 
negative pull sign. A pre-test probability of 75% would increase to a post-test probability of 
99% after a positive pull sign, and decrease to 42% with a negative sign.
After multivariate analysis of a model including endoscopic findings of rings, narrowing, 
furrows, crêpe-paper mucosa, plaques, decreased vascularity, erosive esophagitis, hiatal 
hernia, and the pull sign, a positive pull sign was the strongest independent predictor of EoE 
cases status (OR 45.5; 95% CI, 5.32–339). The other features that remained independent 
were rings (OR 5.75; 95% CI, 1.09–30.4), furrows (12.8; 2.64–61.7), and lack of a hiatal 
hernia (0.21; 0.05–0.94).
There were few differences in demographics and symptoms between the EoE cases who 
were pull sign positive and those who were pull sign negative (Table 3). However, 
endoscopic findings tended to be more common in the pull sign positive cases, including 
rings (81% vs 60%; p = 0.06), narrowing (41% vs 15%; p = 0.03), furrows (94% vs 60%; p 
< 0.001), plaques (56% vs 25%; p = 0.02), and decreased vascularity (70% vs 25%; p < 
0.001). There was also a trend toward a higher eosinophil count in the EoE cases that were 
pull sign positive (158 vs 101 eos/hpf; p = 0.06). There were no significant differences in 
histologic findings, including lamina propria fibrosis (38% vs 44%; p = 0.72) in EoE cases 
with and without a positive pull sign (Table 3).
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We were able to assess interobserver agreement between the corresponding author and 2 
additional endoscopists on a total of 21 subjects. The overall agreement was 90%, 
corresponding to a kappa of 0.81 (p < 0.001). Depending on the endoscopist, agreement 
ranged from 88% to 92%, corresponding with a kappa of 0.75 to 0.85 (p = 0.01 and 0.001, 
respectively).
The pull sign and response to treatment
A total of 58 EoE cases had both pull sign and histologic data available after treatment. The 
vast majority of this cohort (55; 95%) received topical steroid treatment. There were 25 
histologic responders (post-treatment max eosinophil count 3 ± 4 eos/hpf) and 33 non-
responders (118 ± 100 eos/hpf). Of the responders, only 5 (20%) had a positive pull sign on 
post-therapy EGD, whereas 26 (79%) of the non-responders had a positive pull sign (p < 
0.001) (Figure 3A). Of note, a positive pull sign at baseline did not predict treatment 
response: 28 of the EoE cases with a positive pull sign responded (55%) compared with 10 
of the pull sign negative cases (63%; p = 0.59).
A paired analysis showed that of the 41 who were pull sign positive at baseline, 18 (44%) 
were pull sign negative after treatment (p = 0.01), suggesting that treatment could improve 
the compliance of the mucosa. This difference was more prominent after stratifying by 
histologic response and repeating the paired analysis. For the 20 histologic responders who 
were pull sign positive at baseline, only 5 (25%) remained positive after treatment (p < 
0.001). In contrast, of the 21 non-responders who were pull sign positive at baseline, 18 
(86%) remained positive after treatment (p < 0.001).
Post-treatment endoscopic findings also correlated with the pull sign (Figure 3B). For 
example, EoE cases with a positive pull sign after treatment were more likely to have rings 
(68% vs 40%; p = 0.03), strictures (48% vs 15%; p = 0.006), narrowing (32% vs 9%; p = 
0.03), plaques (44% vs 9%; p = 0.002), and decreased vascularity (60% vs 6%; p < 0.001).
Discussion
The typical endoscopic findings of EoE have been shown to be commonly encountered, but 
are not specific or pathognomonic for EoE.3, 4, 6, 7 A novel endoscopic finding, the 
esophageal biopsy “pull” sign, has recently been observed by other investigators,12 but both 
the diagnostic utility and responsiveness to treatment of this sign were unknown. We used a 
prospective cohort study to address these questions and found that the pull sign was highly 
specific for EoE and responsive to retreatment, with resolution of the pull sign after 
successful therapy. However, in contrast to our hypothesis, we did not find a clear link 
between the pull sign and the presence of lamina propria fibrosis, though the pull sign was 
associated with most of the other endoscopic findings of EoE.
This sign has been noted in one other study reported as a letter to the editor.12 Moawad and 
colleagues prospectively assessed 48 adults with esophageal eosinophilia, 39 of whom had 
EoE and 9 of whom had PPI-REE. Of the 48, half had resistance appreciated when obtaining 
an esophageal biopsy specimen. They found very few differences between the positive and 
negative groups, though patients with a positive sign were younger and more likely to have a 
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stricture requiring dilation. Our results were similar when comparing EoE cases with and 
without the pull sign, with younger patients having a positive sign, and with generally few 
differences otherwise noted between the groups. We did not observe the same increase in 
stricture rate and dilation in the EoE cases that were pull sign positive, and because their 
study did not include non-EoE controls or post-treatment data, we cannot directly compare 
the results of our diagnostic utility or treatment response analyses. We are not aware of any 
other investigations reporting on this new endoscopic finding in EoE.
Can the known pathogenesis of EoE help to explain the specificity of the positive pull sign 
in EoE cases? Although EoE is an inflammatory condition, there are also a number of 
mechanisms that lead to increased fibrosis.10, 29–35 EUS studies show that the esophageal 
wall is thickened in EoE compared with controls,36, 37 and that this thickening can partially 
or completely resolve after treatment.38 This is similar to the resolution of lamina propria 
fibrosis that has been reported after treatment as well.32, 39–42 Based on esophagectomy 
specimens, both eosinophilic inflammation and fibrosis can be seen transmurally in 
EoE,33, 43 processes that likely impact the mechanical properties of the esophagus. More 
recently, reduced esophageal compliance as a consequence of EoE has been shown using a 
functional luminal impedance probe, and this compliance also improves after treatment.44, 45 
Because the typical esophageal biopsy specimens that are obtained to assess histologic 
disease activity in EoE are largely restricted to the epithelium, it is difficult to determine the 
extent of transmural esophageal remodeling that is present in routine clinical practice 
without specialized testing.15, 33, 43 Moreover, subtle esophageal narrowing could be missed 
at the time of endoscopy,46 which would imply that remodeling adverse events of EoE could 
also be missed.
We would hypothesize that the pull sign is a potential proxy indicator for this remodeling 
process, and as such is simple and fast to assess with standard equipment. Although our 
results do not show an association between the pull sign and lamina propria fibrosis, this is 
not definitive. Only a sub-set of the EoE cases had subepithelial tissue on biopsy to assess, 
and mucosal biopsy depth is inadequate to accurately evaluate submucosal levels, so the 
study may have been underpowered for this analysis. More interesting was the fact that the 
pull sign resolved in the EoE cases that responded to treatment, both overall and on a paired 
analysis, and this resolution was also associated with improvement in the other endoscopic 
features. This could imply that in these patients who responded, the underlying remodeling 
process has also improved.39–42 In addition, the pull sign was highly specific for EoE and 
was the strongest independent endoscopic predictor of EoE case status. Therefore, it could 
have clinical utility in a diagnostic algorithm when present, as it greatly impacts the post-test 
probability of having EoE.
There are limitations of this study to discuss. First, this study was conducted at a single 
center and only enrolled adults, so we cannot comment on the generalizability of these 
findings or whether a pull sign could be appreciated in children. Although lamina propria 
fibrosis has been described in children,39, 41 overt signs of endoscopic remodeling such as 
rings, strictures, or narrowing are typically less prevalent in this age range.4, 5 Second, the 
pull sign is a subjective endoscopic finding. In this study, we attempted to minimize the 
impact of this by having all patients assessed by the same endoscopist before the 
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confirmation of the EoE diagnosis and before histologic findings were reported. Given the 
nature of our study design, we were not able to truly blind the endoscopist from the 
appearance of the esophagus. Although we acknowledge that the visible presence of other 
endoscopic findings of EoE could have impacted on the reporting of the pull sign, it was still 
assessed as an independent sign. Additionally, this sign will be elicited in the setting of 
available endoscopic findings, so the relevance of the data presented here to the clinical 
context remains high. We would also note that in practice this sign is not subtle. Indeed, at 
least anecdotally, both the endoscopy technicians and nurses in our procedure rooms could 
tell when excess force had to be used to remove esophageal biopsy specimens, although 
those responses were not formally recorded as part of this study. Our pilot data on 
interobserver agreement would support this, as we observed very good agreement for the 
sign. However, larger studies are necessary to confirm this preliminary finding, and future 
studies could also include efforts to formally measure the pulling force transmitted across 
the biopsy forceps. Third, the majority of subjects were treated with topical steroids, so we 
did not have the power to assess whether there was a difference in pull sign frequency after 
treatment with dietary elimination. Fourth, we only used a single forceps model during this 
study. Although that allowed a consistent assessment of the pull sign, it is a limitation that 
multiple forceps models were not tested. Finally, we were not able to correlate the pull sign 
with objective measures of full thickness esophageal remodeling such as endoscopic 
ultrasound or functional luminal impedance, or correlate these measures with lamina propria 
fibrosis, but these are a future direction for research.
There are also a number of strengths to this study. It was a prospective study including a 
large number of EoE cases and controls, with systematic recording of data and findings, and 
with post-treatment follow-up. Because we included both cases and controls, we were able 
to assess the specificity and diagnostic utility of the pull sign, and because we followed 
patients after treatment, we were able to assess the responsiveness of the sign to therapy. 
The data presented here, then, are unique in the literature, and we feel the study 
methodology lends validity to the findings.
In conclusion, this prospective study showed that a new endoscopic finding, the esophageal 
biopsy “pull” sign, is highly specific for EoE. A patient with this sign is very likely to have 
EoE, and this sign is rarely seen in non-EoE controls. Moreover, in patients with EoE who 
have a histologic response to treatment, the pull sign often resolves. Given that fibrosis is a 
major consequence of EoE and that transmural assessment of disease activity is difficult, the 
pull sign may be a simple and easily obtained metric of esophageal remodeling.
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EoE Eosinophilic Esophagitis
Eos/hpf eosinophils per high-power field
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PPI proton pump inhibitor
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PPV positive predictive value
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Figure 1. 
Endoscopic examples of a positive pull sign (A–C). In all images, the mucosa tents with 
pulling and the biopsy forceps are unable to be fully closed. When attempting to remove the 
biopsy sample, there is noticeable resistance.
Dellon et al. Page 14
Gastrointest Endosc. Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. 
Diagnostic utility of the pull test, as illustrated using likelihood ratios. The pre-test 
probability (before assessing the pull sign) of having EoE is on the x-axis. The post-test 
probability (after assess the pull sign) is on the y-axis, and is impacted by whether the pull 
sign is positive (solid line) or negative (dashed line). Post-test probabilities were calculated 
using Bayes Theorem.
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Figure 3. 
(A) The pull sign and response to treatment. Proportion of EoE cases with a positive pull 
sign at baseline before treatment (black bar), and after treatment with non-responders noted 
with the light gray bar, and responders noted with the dark gray bar. The proportion of cases 
with a positive pull sign is significantly reduced in those with histologic response to 
treatment, defined as a biopsy with <15 eos/hpf. (B) The pull sign and endoscopic findings 
after treatment. Endoscopic findings are more common after treatment in the pull sign 
positive EoE cases (black bars) than in the pull sign negative cases (gray bars).
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Table 1
Clinical, endoscopic, and histologic characteristics of the EoE cases and non-EoE controls
Non-EoE controls
(n = 121)
EoE
(n = 83)
P value
Age at diagnosis (mean ± SD) 51.0 ± 13.5 37.7 ± 13.2 < 0.001
Male (n, %) 44 (36) 54 (65) < 0.001
White (n, %) 98 (81) 77 (93) 0.02
Symptoms/EGD indication (n, %)
  Dysphagia 88 (73) 80 (96) < 0.001
  Heartburn 85 (70) 15 (18) < 0.001
  Abdominal pain 10 (8) 6 (7) 0.79
  Nausea/vomiting 11 (9) 2 (2) 0.06
Atopic disorders (n, %)
  Asthma 30 (25) 21 (26) 0.86
  Atopic dermatitis 9 (7) 4 (5) 0.48
  Allergic rhinitis/sinusitis 64 (53) 49 (60) 0.29
  Food allergies 18 (15) 33 (41) < 0.001
  Any atopic disease 72 (60) 55 (68) 0.23
EGD findings at baseline (n, %)
  Normal 17 (14) 3 (4) 0.01
  Rings 11 (9) 63 (76) < 0.001
  Stricture 24 (20) 22 (27) 0.26
  Narrowing 5 (4) 29 (35) < 0.001
  Furrows 6 (5) 71 (86) < 0.001
  Crêpe-paper 2 (2) 6 (7) 0.04
  White plaques/exudates 4 (3) 40 (48) < 0.001
  Decreased vascularity 5 (4) 49 (59) < 0.001
  Erosive esophagitis 18 (15) 2 (2) 0.003
  Hiatal hernia 63 (52) 11 (13) < 0.001
  Dilation performed 37 (31) 29 (35) 0.51
Baseline max eosinophil count (mean ± SD) 1.9 ± 5.8 144.4 ± 119.9 < 0.001
Baseline histology findings (n, %)*
  Eosinophil degranulation 9 (8) 75 (95) < 0.001
  Eosinophil microabscess 2 (2) 56 (71) < 0.001
  Basal zone hyperplasia 13 (12) 39 (51) < 0.001
  Spongiosis 42 (38) 73 (92) < 0.001
  Sub-epithelial stroma present 30 (27) 46 (58) < 0.001
    Lamina propria fibrosis 3 (10) 18 (39) 0.004
*
Data available for 190 subjects
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Table 2
Diagnostic performance of the pull sign for EoE
Non-EoE controls
(n = 121)
EoE
(n = 83)
P value
Pull sign
  Negative 119 (98) 20 (24) < 0.001
  Positive 2 (2) 63 (76)
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Table 3
Characteristics of EoE cases stratified by the esophageal pull sign
Pull sign - EoE cases
(n = 20)
Pull sign + EoE cases
(n = 63)
P value
Age at diagnosis (mean ± SD) 45.2 ± 16.5 35.4 ± 11.1 0.003
Male (n, %) 10 (50) 44 (70) 0.11
White (n, %) 19 (95) 58 (92) 0.66
Symptoms/EGD indication (n, %)
  Dysphagia 19 (95) 61(97) 0.70
  Heartburn 4 (20) 11 (17) 0.80
  Abdominal pain 3 (15) 3 (5) 0.12
  Nausea/vomiting 2 (10) 0 (0) 0.01
Any atopic disease 13 (65) 42 (69) 0.75
EGD findings at baseline (n, %)
  Normal 2 (10) 1 (2) 0.08
  Rings 12 (60) 51 (81) 0.06
  Stricture 4 (20) 18 (29) 0.45
  Narrowing 3 (15) 26 (41) 0.03
  Furrows 12 (60) 59 (94) < 0.001
  Crêpe-paper 0 (0) 9 (10) 0.15
  White plaques/exudates 5 (25) 35 (56) 0.02
  Decreased vascularity 5 (25) 44 (70) < 0.001
  Dilation performed 7 (35) 22 (35) 0.99
    Max size (mean mm ± SD) 15.9 ± 2.6 13.3 ± 3.3 0.07
Baseline max eosinophil count (mean ± SD) 100.7 ± 95.8 158.3 ± 124.1 0.06
Baseline histology findings (n, %)*
  Eosinophil degranulation 16 (89) 59 (97) 0.18
  Eosinophil microabscess 11 (61) 45 (74) 0.30
  Basal zone hyperplasia 6 (35) 33 (55) 0.15
  Spongiosis 15 (83) 58 (95) 0.10
  Sub-epithelial stroma present 9 (50) 37 (61) 0.42
    Lamina propria fibrosis 4 (44) 14 (38) 0.72
Treatment response (<15 eos) 10 (63) 28 (55) 0.59
*data available for 79 subjects
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